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ABSTRACT 
Background: Older adults with multiple sclerosis (MS) experience age-related declines in 
physical and cognitive function that may be compounded by the disease and its progression. 
However, the extent to which impairments in physical and cognitive function are manifestations 
of MS and disease progression, reflective of the general aging process, or perhaps two 
detrimental processes exacerbating the synergistic effects of the other is relatively unknown.  
Further, there is very little known about managing the progression and consequences of MS in 
older adults. Physical activity participation might provide a protective or potentially restorative 
effect on the mechanisms associated with aging and MS that influence physical and cognitive 
function.  
 
Objectives: The present study examined physical and cognitive function in 40 older adults with 
MS (i.e., 60 years of age and older) compared to 40 age- and sex-matched healthy older adults in 
the general population and the extent to which objectively measured physical activity and 
sedentary behavior were associated with these functions. 
 
Methods: Participants initially underwent the cognitive assessments, followed by the physical 
function assessments. The order of tests was standardized and participants were provided seated-
rest between the administrations of the physical function assessments. Participants were then 
instructed to wear an accelerometer and document wear time in a log book for a seven-day 
period after the testing session. 
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Results: Independent samples t-tests indicated that older adults with MS performed worse on all 
measures of physical function and one measure of cognitive function (i.e., information 
processing speed) compared to healthy controls. ANCOVAs indicated that older adults with MS 
engaged in less moderate-to-vigorous physical activity (MVPA) (minutes/day) and more 
sedentary behavior (minutes/day) compared to healthy controls. Partial Pearson correlations 
demonstrated that levels and patterns of physical activity were significantly associated with a 
majority of physical function variables but not cognitive function variables in both older adults 
with MS and healthy controls but to a greater extent in older adults with MS. Partial Pearson 
correlations further demonstrated that levels and patterns of sedentary behavior were 
significantly associated with a majority of physical function variables but not cognitive function 
variables primarily in older adults with MS. Linear regression analyses further demonstrated that 
the low levels of MVPA (minutes/day) partially accounted for differences in physical and 
cognitive function variables between older adults with MS and healthy controls. 
 
Conclusions: The present results indicate that compared to healthy controls, older adults with 
MS experience large declines in all areas of physical function, but only one area of cognitive 
function (i.e., information processing speed), and engage in lower levels of MVPA and higher 
levels of sedentary behavior. Further, both levels and patterns of physical activity, namely 
MVPA, and sedentary behavior should be a focus of clinical rehabilitation and behavioral 
interventions for the promotion of healthy aging in older adults with MS. 
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Chapter 1: 
Introduction 
Multiple Sclerosis (MS) is a chronic, often progressive, neurologic disease involving 
inflammation, axonal demyelination and transection, and neurodegeneration within the central 
nervous system (CNS) (Trapp & Nave, 2008) with an estimated prevalence of 1 per 1000 people 
in the United States (Mayr et al., 2003). The damage within the CNS manifests as the 
accumulation of impairments and symptoms, including physical and cognitive disability 
(Confavreux & Vukusic, 2006a). Of the 400,000 adults living with MS in the United States, an 
estimated 30% of adults are between 55–64 years of age and 15% of adults are 65 years of age 
and older (Minden et al., 1993). There is additional evidence of a shift in the peak prevalence of 
MS among older adults. For example, in Manitoba, Canada, the peak prevalence of MS occurred 
at 35–39 years of age, with no documented cases beyond an age of 64 years, in 1984 (Marrie et 
al., 2010). By 2004, the peak prevalence was at 55–59 years of age, with cases of MS 
documented beyond 80 years of age (Marrie et al., 2010). This coincides with increased survival 
of those with MS as 90% of adults with MS may live to be 70 years of age or older (Hurwitz, 
2011). Therefore, there are greater numbers of older adults living with MS than ever before, and 
this trend will continue over the next decades. 
Older adults with MS undergo age-related declines in physical and cognitive function that 
may be compounded by the disease and its progression (Awad & Stüve, 2010; Stern et al., 2010). 
There is evidence of a faster rate of disability progression among older adults with MS (Minden 
et al., 2004) and older age is a predictor of reaching disability milestones in MS (e.g., median age 
for unilateral assistance during walking is nearly 65 years) (Confavreux & Vukusic, 2006b). 
Older adults with MS report limitations in activities of daily living (Finlayson & Van Denend, 
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2003) and express concerns about future losses of function and mobility that normally occur with 
aging (Finlayson, 2004). Aging is a risk factor for cognitive dysfunction. In a previous cross-
sectional study, older adults with MS (59–74 years of age) performed worse on a single 
neuropsychological measure of information processing speed compared to healthy age- and sex-
matched controls (Bodling et al., 2009). A very recent study demonstrated that the progression of 
decline in motor, or physical function, is amplified by aging in persons with MS; however, the 
degree of cognitive impairment did not seem to vary across the lifespan (Roy et al., 2016). 
There are limitations of previous research that provide rationale for continued 
examination of physical and cognitive function among older adults with MS. For example, the 
existing research on physical function in older adults with MS has mostly included self-report 
measures (Finalyson, 2002; Finlayson & Van Denend, 2003; Finlayson, 2004). Those may suffer 
from validity, reproducibility, and applicability for use in different cultures and nations, similar 
to research in normal aging populations (Guralnik et al., 1989). There is further limited research 
examining direct, head-to-head comparisons of physical and cognitive function in older adults 
with MS and in older adults without MS or other neurological diseases. Therefore, direct, 
objective, and comprehensive research is absolutely warranted to examine the extent to which 
impairments in physical and cognitive function are manifestations of MS and disease 
progression, reflective of the general aging process, or perhaps two detrimental processes 
exacerbating the synergistic effects of the other.  
There is very little known about managing the progression and consequences of MS in 
older adults. This is based on the fact that older adults with MS are often excluded from research. 
For example, there are 13 FDA-approved disease-modifying agents that represent the first line of 
therapy for persons with MS; these have only been tested in younger and middle-aged adults but 
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not older adults (Multiple Sclerosis Coalition, 2015; Stern et al., 2010). Some data suggest that 
these agents may have no effect on disease progression in older adults with MS (Shirani et al., 
2015). Therefore, a focus on behavioral approaches, such as physical activity, may represent a 
novel approach for healthy aging with MS (Motl et al., 2016). Previous evidence suggests that 
older adults with MS are not engaging in sufficient amounts of physical activity for accruing 
health benefits and are engaging in high amounts of sedentary behavior (Klaren et al., 2016). 
However, there is much evidence on the benefits of physical activity in young and middle-aged 
adults with MS (Motl, 2014; Motl & Sandroff, 2015), older adults in the general population 
(Taylor et al., 2004), and in those with chronic diseases that impact mobility (de Vries et al., 
2012). For example, in persons with MS, there is evidence of associations between physical 
activity and brain volume, walking performance, cognition, and symptoms of fatigue and pain 
(Motl, 2014). Physical activity participation may therefore provide a protective or potentially 
restorative effect on the mechanisms associated with aging and MS that influence physical and 
cognitive function (Keysor, 2003). 
The current study involved the examination of physical and cognitive function in older 
adults with MS (i.e., 60 years of age and older) compared to age- and sex-matched healthy older 
adults in the general population and the extent to which objectively measured physical activity 
and sedentary behavior were associated with these functions. Based on previous research, the 
first hypothesis is that persons with MS would demonstrate greater impairments in all measures 
of physical and cognitive function compared to healthy older adults. The second hypothesis is 
that physical activity would be lower and sedentary behavior would be higher in older adults 
with MS compared to healthy older adults. The third hypothesis is that physical activity would be 
positively associated and sedentary behavior would be negatively associated with physical and 
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cognitive function in older adults with MS and in healthy older adults. Such data would provide 
information on the magnitude of decline in physical and cognitive function in older adults with 
MS and identify whether physical activity or sedentary behavior might account for the 
differences in function. The results of this study would further provide a foundation for clinical 
rehabilitation and behavioral interventions, such as physical activity, for the promotion of 
healthy aging in older adults with MS.  
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Chapter 2: 
Review of Literature 
The current review of literature provides information for developing the rationale for the 
present study of the characterization of physical and cognitive function, physical activity, and 
sedentary behavior in older adults with MS. This chapter first describes the pathophysiological 
mechanisms that contribute to physical and cognitive disability in persons with MS as well as the 
epidemiology of MS (i.e., incidence and prevalence). This chapter then discusses and reviews 
research examining physical and cognitive function in older adults with MS. This chapter further 
examines research on the associations of physical and cognitive function, physical activity, and 
sedentary behavior in MS. This chapter then concludes with a summary of the rationale and 
design of the current study. 
 
Pathophysiology of MS 
MS can be described as an immune-mediated and neurodegenerative disease of the CNS. 
The first diagnostic criteria were known as Charcot’s triad, after Jean Martin Charcot, a French 
clinician and investigator who first recognized the disease in 1868 (Frohman et al., 2011). These 
criteria consisted of scanning speech, intention tremor, and nystagmus. Over the years, the 
diagnostic criteria have expanded and become more precise (i.e., Poser and McDonald criteria) 
that have greatly refined the ability to confirm a diagnosis. 
MS often initially presents as clinically isolated demyelinating syndrome (CIS) and is 
associated with clear dissemination of silent or subclinical lesions in the brain or spinal cord 
(Frohman et al., 2011). Of the CIS cases, approximately 30–70% result in a diagnosis of MS 
(Miller et al., 2012).  Inflammation is the hallmark of MS and the inflammatory processes are 
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caused by an autoimmune response within the CNS in which the body’s own immune system 
attacks the myelin sheaths surrounding axons (Trapp & Nave, 2008). The acute inflammatory 
process involves an increase in adhesion molecules on the endothelium of the brain and spinal 
cord that allow autoreactive leukocytes to enter the CNS via the blood-brain barrier. These 
leukocytes then proliferate and trigger a cascade of events, including the activation of T-cells, 
microglia, and cytokines, that contribute to the acute inflammatory demyelination by reinforcing 
the attack on myelin, oligodendrocytes, and axons. This damage leads to the interruption of 
action potentials and axonal conduction and loss of remyelination capabilities, leading to the 
clinical signs and symptoms of MS (Vollmer, 2007). While many changes in the CNS occur in 
the white matter, there are also changes in the gray matter. The inflammation of the white matter 
is a result of T-cell activation whereas the gray matter inflammation seems to result from myelin 
reactive B-cells and the production of myelin-specific antibodies (Frohman et al., 2011). 
 As a result of the acute inflammation and associated demyelination, plaques, or lesions, 
are often formed in the CNS (Frohman et al., 2011). Glial cells in the CNS, such as astrocytes, 
accumulate in the areas of demyelination and this proliferation leads to the formation of glial 
scars that further prevent remyelination and any recovery processes to occur. There is also a 
chronic increase in the expression of sodium channels within the axon membrane, followed by 
the reversal of the sodium-calcium exchanger (Frohman et al., 2011). Both processes contribute 
to axonal dysfunction and neuronal degeneration. The resulting axonal transections are correlated 
with CNS atrophy and lead to the irreversible disabilities common in MS (Vollmer, 2007).  
 There are relapsing and progressive types of MS. The initial course of disease in 
approximately 85–90% of persons with MS is of the relapsing-remitting subtype (RRMS), that is 
characterized by relapses, or neurological exacerbations, followed by periods of remissions 
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(Trapp & Nave, 2008). Approximately 65% of persons with RRMS will further progress to 
another phase, referred to as Secondary Progressive MS (SPMS), after a period of approximately 
19 years after initial diagnosis (Trapp & Nave, 2008). SPMS is characterized by progressive 
neurological decline, without definite periods of remission. In contrast to patients who initially 
present with RRMS, some patients experience a progressive course of disability from diagnosis, 
without any evidence of relapses or periods of remission. This is identified as Primary 
Progressive MS (PPMS) and describes approximately 10–15% of persons with MS (Trapp & 
Nave, 2008). 
As a person with MS ages, the pathophysiological changes associated with the normal 
aging process may affect the severity of impairment and disability (Stern et al., 2010). Aging 
itself is characterized by the presence of a chronic, systemic low-grade inflammation and is 
influenced by chronic antigenic stimulations, such as infections (i.e., Epstein-Barr Virus (EBV)) 
and a general increase in the production of pro-inflammatory cytokines (i.e., IL-6 and TNF-α) 
(Sanai et al., 2016). There are further alterations in distribution and functionality of T-cells, 
particularly T-regulatory cells, and dysregulated microglia that lead to the neuroinflammatory 
pathology of aging (Kleinewietfeld & Hafler, 2014). These alterations, as well as the decreased 
thymic epithelial tissue and thymopoeisis associated with aging, contribute to reduced 
responsiveness to new antigens and subsequent increased frequency of infections. Lastly, in both 
MS and aging, there is the existence of bidirectional communication between the peripheral 
immune system and the brain mainly through immune molecules and cells that cross the blood-
brain barrier. Therefore, the already compromised and dysfunctional immune system in MS will 
further be affected by the pathologies that occur with normal aging, thus driving the transition 
from RRMS to PPMS or SPMS.  
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Evidence has demonstrated that the level of inflammation typically decreases in persons 
with MS with age. Indeed, a previous study in elderly persons with MS demonstrated the density 
of pro-inflammatory cells and associated axonal injury to decline to levels similar to those found 
in age-matched controls (Awad & Stüve, 2010). However, neurodegeneration is amplified by 
factors related to aging, such as progressive degeneration of cells and loss of regenerative 
capacity (Knapowski, 2002). In aging individuals, the reduced capacity to regenerate injured 
tissues or organs is one of the hallmarks of senescence (Rist & Franklin, 2008). The age-related 
decrease in the efficiency of repair is often related to impaired stem and progenitor cell 
functionality, either through intrinsic or environmental changes in the aged tissue. Like other 
regenerative processes, remyelination is affected by aging. In persons with MS, there is further 
evidence that the failure of remyelination does not occur at the level of cell recruitment, but the 
lack of oligodendrocyte precursor cells differentiating into myelinating oligodendrocytes (Rist & 
Franklin, 2008). The tissue loss due to MS results in a 0.7%−1.0% loss of brain volume per year 
in persons with MS, compared to 0.1%−0.3% loss per year from normal aging in healthy 
subjects (Sanai et al., 2016). In the general aging population, there is a focal loss in thalamic 
volume; this loss is even more pronounced in persons with MS (Hasan et al., 2011) and is 
associated with physical disability (Niepel et al., 2006) and cognitive dysfunction (Derache et al., 
2006). In a previous study, thalamic volume loss in persons with MS was correlated with 
Expanded Disability Status Scale (EDSS) scores after adjusting for natural aging and whole 
brain lesion volume (Hasan et al., 2011). This therefore suggests that MS pathology has a 
neurodegenerative component independent from lesions, especially in older adults, which 
contributes to the declines in function. 
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Epidemiology of MS 
MS is one of the most common neurological diseases worldwide, with an estimated 
prevalence of more than two million cases (Kingwell et al., 2013) and a range of incidence rates 
of approximately 1 per 100,000 persons/years to 12 per 100,000 persons/years (Mayr et al., 
2003). The disease typically presents in the 3rd or 4th decade of life (Mayr et al., 2003), and 
worldwide incidence of MS peaks at approximately 30 years of age (Noonan et al., 2002). In 
terms of sex differences, MS is more common in women such that women are affected three 
times more often than men (Noonan et al., 2002). MS is not considered a fatal disease, although 
the progression of the disease does cause significant life changes. Average survival has been 
reported to be approximately 38 years following diagnosis (Hirst et al., 2008). With the increase 
of disease-modifying therapies, lifespan has substantially increased over the past few decades 
among persons with MS (Hurwitz, 2011). Indeed, approximately 90% of adults with MS may 
live to be 70 years of age or older (Hurwitz, 2011). There is additional evidence of a shift in the 
peak prevalence of MS among older adults. For example, in Manitoba, Canada, the peak 
prevalence of MS occurred at 35–39 years of age, with no documented cases beyond an age of 
64 years, in 1984 (Marrie et al., 2010). By 2004, the peak prevalence was at 55–59 years of age, 
with cases of MS documented beyond 80 years of age (Marrie et al., 2010). Of the 400,000 
adults living with MS in the United States, an estimated 30% of adults are between 55–64 years 
of age and 15% of adults are 65 years of age and older (Minden et al., 1993).  
MS is most prevalent in Western Europe and North America, followed by regions in 
Central and Eastern Europe and Australia (Koch-Henriksen & Sørenson, 2010). The regions with 
the lowest prevalence are Africa, Asia, and the Middle East. Further, MS seems to be most 
prevalent in areas above 40° latitude (Frohman et al., 2011). MS is therefore more common in 
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individuals with Northern European ancestry compared to individuals of African, Asian, or 
Hispanic descent (Mayr et al., 2003). In the United States, MS is most prevalent in the northern 
states compared to the southern states, with an overall prevalence of 1 per 1000 persons (Mayr et 
al., 2003).  
While the cause of MS is still currently unknown, the risk of developing MS seems to be 
related to genetics as well as the environment. A previous analysis by an international 
consortium identified 29 disease susceptibility genes with direct or indirect influences on the 
immune system (International Multiple Sclerosis Genetics Consortium, 2011). For example, the 
risk of MS increases from 1% to 2–4% if a first-degree relative is affected (Frohman et al., 
2011). Epidemiological data has also identified specific environmental risk factors for MS. For 
example, EBV is often associated with an increased risk of MS, especially if infected during 
adulthood (Lauer, 2010). Another study demonstrated that EBV is the only infectious agent that 
explains many of the key features of MS epidemiology (Ascherio & Munger, 2007). This study 
further reported that approximately 99% of persons with MS have previously been infected with 
EBV; this is compared to 95% of the general adult population (Ascherio & Munger, 2007). 
However, when compared to individuals infected with EBV in early childhood, the incidence of 
MS is 10-fold less among EBV-negative individuals and 2 to 3-fold greater among individuals 
infected with EBV later in life, based on a history of mononucleosis (Ascherio & Munger, 2007). 
Therefore, there is a 20-fold increase in risk among individuals with a history of mononucleosis 
compared with those who are EBV-negative. Tobacco smoking has further been identified as a 
risk factor for MS, with the relative risk for MS development approximately 1.5 for smokers 
compared with non-smokers (Wingerchuk, 2012). Vitamin D deficiency may also play a role in 
the susceptibility for the disease (Pugliatti et al., 2008). Due to the increase in prevalence of MS 
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in areas above 40° latitude (i.e., farther from the Equator) (Frohman et al., 2011), Vitamin D 
could be a potential mediator between latitude, or sunlight exposure, and risk for MS (Ascherio 
et al., 2010). 
 
Physical and Cognitive Function in Older Adults with MS 
Older adults with MS as well as healthy older adults in the general population experience 
impairments in overall function, with physical and cognitive function being two of the most 
affected domains (Stern et al., 2010). Indeed, the growing cohort of older adults with MS 
undergoes age-related declines in physical (e.g., ambulatory and balance dysfunction and muscle 
weakness) and cognitive function (i.e., information processed speed) that may be further 
compounded by the disease and its progression (Awad & Stüve, 2010; Stern et al., 2010). While 
there is much evidence on physical and cognitive function in older adults in the general 
population, there is limited evidence in older adults with MS, particularly using objective, 
performance measures of function. Further, the extent to which impairments in physical and 
cognitive function are manifestations of MS or of the aging process is generally unknown as 
there is scarce evidence of direct, head-to-head comparisons of function in older adults with MS 
and adults without MS or other neurological diseases. This section of the chapter will review the 
evidence on physical and cognitive function in older adults with MS and how they may differ 
from healthy older adults without MS. 
 
Physical Function in Older Adults with MS 
There is evidence of a faster rate of disability progression among older adults with MS 
(Minden et al., 2004) and older age is a predictor of reaching disability milestones in MS (e.g., 
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median age for unilateral assistance during walking is nearly 65 years) (Confavreux & Vukusic, 
2006b). In a study of persons with MS (n = 2156) examining demographic and clinical 
characteristics of those over and under 65 years of age, disability was significantly higher in 
older versus younger adults (Minden et al., 2004). Further, not surprisingly, a higher percentage 
of persons with MS over 65 years of age required a cane or bilateral support to walk 25 feet or 
were completely wheelchair dependent (Minden et al., 2004). In another study of 53 older adults 
with MS (mean age = 73 years), all participants reported problems with mobility (Klewer et al., 
2001). As disability often increases with age, this same study reported average EDSS scores to 
be above 6.0 (requiring ambulatory assistance) in 96.2% of participants, and 69.8% required 
wheelchairs for their mobility (EDSS score above 6.5). Due to the high prevalence of assistive 
device use in older adults and high levels of disability, the risk of falling is also more common in 
older adults (Nilsagard et al., 2009). 
 There have been three qualitative studies that have examined disability and mobility loss 
from the perspectives of older adults with MS (Finalyson, 2002; Finalyson & Van Denend, 2003; 
Finalyson, 2004). The first study involved a descriptive analysis of three separate research 
studies conducted in Canada and the United States that examined the health profile of 440 older 
adults with MS (mean age = 64 years) (Finalyson, 2002). In the overall sample, the most 
common symptoms reported by participants were fatigue (82.6%), problems with balance 
(81.1%), and weakness (73.3%). Mobility impairment was further a major problem identified by 
participants. Overall, 13.4% of participants used a walking aid all the time and 14.1% were 
confined to a wheelchair. Difficulty with transportation was reported by 34.6% of participants. 
Participants also reported difficulties with activities of daily living, including inability to do 
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heavy housework independently (81.1%) or make a hot meal without assistance (50.2%). 
Further, 39.8% of participants rated their health as poor or bad.  
  In the second study, researchers examined the mobility experiences of older adults with 
MS, including mobility-related concerns and the consequences and challenges of mobility loss 
(Finlayson & Van Denend, 2003). A thematic analysis explained three factors contributing to 
mobility including the reality of having MS, mobility needs, and contextual factors. For example, 
participants expressed concerns about the continual declines in mobility and losing 
independence. The participants reported that MS affected their ability to get around and the 
importance of trying to remain in control over their mobility experiences. Further, participants’ 
experiences of mobility were associated with mourning losses, taking action, and contemplating 
their future. The third qualitative study further examined the health-related concerns and needs of 
27 older adults with MS (ages 55–81 years of age) (Finalyson, 2004). Overall, ‘fear of the future’ 
was identified as a predominant concern among the participants. Participants expressed concerns 
about experiencing further loss of mobility and independence and becoming a burden on 
caregivers.  
One recent study examined the validity of the Short Physical Performance Battery 
(SPPB) in older adults with MS (Motl et al., 2015). The SPPB is an objective measure of 
physical function commonly used in older adults in the general population (Guralnik et al., 
1994). This study reported that older adults with MS (50 years of age and older) (n = 48), had a 
median SPPB score of 9.0 (Motl et al., 2015), and this approached the expected SPPB score for 
non-disabled, healthy adults 71 years of age and older (mean = 9.2) (Guralnik et al., 2000). The 
lower extremity strength component of the SPPB demonstrated larger decrements in physical 
function (median score of 1.0 (IQR = 1.0)) compared to the other measurements of gait speed 
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(median score of 4.0 (IQR = 1.0)) and balance (median score of 4.0 (IQR = 1.0)), as lower scores 
are indicative of worse function. 
 
Cognitive Function in Older Adults with MS 
Cognitive impairment is present in an estimated 45–65% of persons with MS, with the 
core deficits as the slowing of information processing speed and episodic memory (Benedict & 
Zivadinov, 2011). Cognitive impairment is very detrimental in persons with MS and can have 
substantial influence on activities of daily living (Kalmar et al., 2008) and employment (Rao et 
al., 1991). One qualitative study examined the perceptions of cognitive function among aging 
adults with MS and their caregivers (Finlayson et al., 2009). The sample consisted of 279 dyads 
of persons with MS (mean age = 62.8 years) and their caregivers. Approximately 61% of persons 
with MS reported cognitive symptoms that interfered to some degree with their ability to engage 
in everyday activities. Further, approximately 62.7% of caregivers reported that their care 
recipients experienced cognitive symptoms. However, eighty dyads (28.7%) disagreed about the 
presence of cognitive symptoms in the person with MS. 
A cross-sectional study of patients with MS (n = 84) from 45 to 81 years of age (mean 
age = 60.6 years) demonstrated that 48% of patients (n = 40) had cognitive impairment based on 
neuropsychological testing, including general cognitive functioning (Wechsler Adult Intelligence 
Scale (WAIS-III), psychomotor speed (Symbol Digit Modalities Test (SDMT), selective 
attention (Stroop Color Naming Test), working memory (Letter-Number Span Test (WAIS-III) 
and the Paced Auditory Serial Addition Test (PASAT)), verbal learning and memory (Hopkins 
Verbal Memory Test-Revised (HVMT-R)), non-verbal memory (Continuous Visual Memory 
Test), and executive function (Wisconsin Card Sorting Test short version (WCST-64) (Smestad 
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et al., 2010). The criteria for cognitive impairment was defined as a score of 1.5 standard 
deviations (SDs) below the mean normative values on at least one subtest in two of the four main 
functional areas (i.e., psychomotor speed, attention, learning/memory, and executive function). 
In general, the typical pattern of cognitive impairment was moderate in magnitude, within areas 
of information processing speed, attention, and memory. This study further demonstrated disease 
course type to be a predictor of cognitive impairment, such that persons with SPMS 
demonstrated increased cognitive impairment compared to persons with RRMS (OR = 2.74, 95% 
CI = 1.01–7.44, p < 0.05).  
Another study demonstrated older adults with MS (59–74 years of age) (n = 245) 
performed worse on measures of information processing speed (i.e., Stroop Color and Word 
Naming Tests) compared to healthy age- and sex-matched controls (n = 188) (Bodling et al., 
2009). That study further demonstrated reductions in information processing speed, across five 
age cohorts (i.e. 18–29, 30–39, 40–49, 50–58, and 59–74 years of age). However, there was no 
group by age interaction, such that persons with MS and healthy controls demonstrated similar 
trajectories of cognitive slowing across the five age cohorts. The major limitation of that study 
was the inclusion of a single domain of cognitive function (i.e., information processing speed) 
rather than a range of outcomes capable of capturing differences across multiple cognitive 
functions, particularly memory, given the high prevalence and impact of memory impairment 
associated with MS (Chiaravalloti & DeLuca, 2008) and aging (Peterson et al., 1997). 
Regarding the mechanisms contributing to the cognitive decline with age in MS, 
evidence in young to middle-aged adults suggests the decline to be moderately related to the 
progression of lesion load in the whole brain and in specific regions, as well as overall brain 
atrophy (Amato et al., 2006). Lesion burden in frontal and parietal white matter was strongly 
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associated with performance on neuropsychological tests requiring sustained complex attention 
and working verbal memory (Sperling et al., 2001). Further, these associations were constant 
over a four-year period, suggesting that disruptions in the frontoparietal subcortical network may 
contribute to the increase in cognitive impairment with age in persons with MS.  
 
Effects of Aging and MS on Physical and Cognitive Function 
Determining the cause of worsening function in older adults with MS is very challenging 
as it is sometimes difficult to differentiate between the normal aging process and MS disease 
progression. Often, it may be the synergistic combination of the two that result in the overall 
decline in function (Sanai et al., 2016). As many of the pathological manifestations of aging and 
MS are similar (i.e., inflammation and neurodegeneration), so are various symptoms and 
impairments, such as reduced muscle strength, balance problems, and cognitive dysfunction. As 
persons with MS age, they are likely to have the same comorbidities as older adults in the 
general population, including hypertension, diabetes, cancer, or Alzheimer’s disease, that may 
further contribute to physical and cognitive impairment (Ploughman et al., 2012). One recent 
study examined differences between persons with MS (n=698; 29−71 years of age) and healthy 
controls (n=226; 18−72 years of age) on motor (i.e., physical function) and cognitive 
performance across the lifespan (Roy et al., 2016). Linear regression models demonstrated an 
impact of aging in all motor and cognitive performance measures with a decline in performance 
with age. However, the age × MS diagnosis interaction effects were only significant for motor 
performance, but not cognitive function. Therefore, the aging process may affect physical and 
cognitive function differently in persons with MS. Additional research using direct comparisons 
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of older adults with MS and older adults without MS is warranted to truly examine and 
characterize the effects of aging and MS on physical and cognitive function. 
 
Physical Activity, Sedentary Behavior, and Function in MS 
There is very little known about managing the progression and consequences of MS in 
older adults, including the declines in physical and cognitive function. In the majority of 
previous research, older adults with MS are often excluded from trials. For example, the 13 
FDA-approved disease-modifying agents that represent the first line of therapy for persons with 
MS have only been tested in younger and middle-aged adults but not older adults (Multiple 
Sclerosis Coalition, 2015; Stern et al., 2010). There is some data that suggest these agents may 
have no effect on disease progression in older adults with MS (Shirani et al., 2015). Therefore, a 
focus on physical activity may represent a novel approach for healthy aging with MS (Motl et al., 
2016).  
Previous evidence suggests that older adults with MS are not engaging in sufficient 
amounts of physical activity for accruing health benefits as well as engaging in high amounts of 
sedentary behavior (Klaren et al., 2016). For example, one previous study demonstrated that 
older adults with MS (i.e., ≥ 60 years of age) spend approximately 12 and 7 fewer minutes per 
day in moderate-to-vigorous physical activity (MVPA) compared with middle-aged (i.e., ages 
40–59) and young adults (i.e., ages 20–39), respectively (Klaren et al., 2016). Only 14% of older 
adults with MS meet public health guidelines for MVPA (i.e., ≥ 30 min/day of MVPA), and this 
was significantly lower when compared with approximately 21% and 28% in middle-aged and 
young adults with MS. Further, this study demonstrated that older adults with MS spend 
significantly more time in sedentary behavior per day (554 minutes) compared with young adults 
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(510 minutes) (Klaren et al., 2016). The very low levels of physical activity and high levels of 
sedentary behavior in older adults with MS may further exacerbate problems associated with 
aging and disease progression. 
By comparison, physical activity participation may provide a protective or potential 
restorative effect on physical and cognitive function in older adults with MS (Keysor, 2003). 
Indeed, there is much evidence on the benefits of physical activity in young and middle-aged 
adults with MS (Motl, 2014), older adults in the general population (Taylor et al., 2004), and in 
those with chronic diseases that impact mobility (de Vries et al., 2012). For example, in young 
and middle-aged adults with MS, there are numerous cross-sectional and longitudinal studies of 
the relationships between free-living or lifestyle physical activity and physical function, such as 
disability (Motl et al., 2012) and walking impairment (Motl et al., 2011). For example, one study 
demonstrated higher levels of premorbid physical activity lessened the rate of disability 
progression over a 24-month period in 269 persons with MS (mean age = 45.9 years), even when 
controlling for confounding variables such as sex or age (Motl et al., 2012). Another study 
examined the association between changes in lifestyle physical activity and walking impairment 
over a 6-month period in persons with RRMS (Motl et al., 2011). The results demonstrated direct 
effects between baseline physical activity and walking impairment (path coefficient = –0.31) and 
follow-up physical activity and walking impairment (path coefficient = –0.16). The second path 
coefficient established that a SD unit change of 1.0 in physical activity was associated with a SD 
unit residual change of 0.16 in walking impairment (Motl et al., 2011). Another cross-sectional 
study of 33 persons with MS demonstrated objectively measured physical activity to be 
significantly correlated with cognitive function, specifically processing speed (pr = 0.35), after 
controlling for sex, age, and education (Motl et al., 2011). A more recent study examined 
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physical activity and its association with volumes of whole brain gray matter and white matter 
and deep gray matter structures in a sample of 39 persons with MS (mean age = 48.7) (Klaren et 
al., 2015). Moderate-to-vigorous physical activity (MVPA), but not light physical activity (LPA), 
was significantly associated with whole brain gray matter volume (pr = 0.37), whole brain white 
matter volume (pr = 0.43), hippocampus (pr = 0.50), thalamus (pr = 0.38), caudate (pr = 0.54), 
putamen (pr = 0.37), and pallidum (pr = 0.50) volumes, even when controlling for sex, age, 
clinical course of MS, and EDSS score. These results suggest that that MVPA is associated with 
volumes of whole brain gray matter and white matter and deep gray matter structures that are 
involved in motor and cognitive functions in MS. The consequences of sedentary behavior have 
also been examined in previous research involving young and middle-aged adults with MS 
(Veldjuijzen van Zanten et al., 2016). One study demonstrated that greater sedentary time, 
measured using accelerometry, was significantly correlated with lower walking endurance (r = 
0.40) and slower walking speed (r = 0.35) in a sample of 82 persons with MS (Hubbard & Motl, 
2015). Another study demonstrated that higher levels of sedentary behavior were negatively 
associated with average daily step count and average number of minutes being active in a sample 
of 21 adults with MS (Cavanaugh et al., 2011). Other reviews have provided evidence that 
exercise training, a subtype of physical activity, demonstrated benefits across a spectrum of 
outcomes including inflammatory factors, neurotrophic factors, and CNS structures (Motl & 
Pilutti, 2012).  
There have been few exercise training interventions designed for older adults with MS. 
For example, one randomized controlled trial (RCT) examined the effects of a 6-month exercise 
training DVD on a variety of physical function outcomes, including strength, mobility, 
flexibility, and balance, in a sample of 24 older adults with MS (50 years of age and older) 
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(McAuley et al., 2015). This study demonstrated a modest effect on the intervention on physical 
function. For example, participants demonstrated an increased SPPB score of ~0.30, a small, 
clinically meaningful difference. Another RCT examined the effects of a 12-week home-based 
exercise program targeting balance, walking, and lower limb muscle strength for reducing fall 
risk in a sample of 13 older adults with MS (50–75 years of age) (Sosnoff et al., 2014). Overall, 
this intervention reduced physiological fall risk in older adults with MS, and this reduced risk 
was associated with improvements in balance.  
 
The Present Study 
There are limitations of previous research that provide rationale for continued 
examination of physical and cognitive function among older adults with MS. For example, the 
existing research on physical function in older adults with MS has included self-report measures 
(Finalyson, 2002; Finlayson & Van Denend, 2003; Finlayson, 2004) that may suffer with 
validity, reproducibility, and applicability for use in different cultures and nations, similar to 
research in normal aging populations (Guralnik et al., 1989). There is further limited research 
examining direct, head-to-head comparisons of physical and cognitive function in older adults 
with MS and older adults without MS or other neurological disease. Research on physical and 
cognitive function in older adults with MS would greatly benefit from objective and 
comprehensive measures.  
The current study involved the examination of physical and cognitive function in older 
adults with MS (i.e., 60 years of age and older) compared to age- and sex- matched healthy older 
adults in the general population and the extent to which objectively measured physical activity 
and sedentary behavior were associated with function. Figure 1 illustrates a model that guided 
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the current study including the mechanisms of aging and MS on physical and cognitive function 
and the potential effects of physical activity and sedentary behavior. Based on previous research, 
the first hypothesis was that persons with MS would demonstrate greater impairments in all 
measures of physical and cognitive function compared to healthy older adults. The second 
hypothesis was that physical activity would be lower and sedentary behavior would be higher in 
older adults with MS compared to healthy older adults. The third hypothesis was that physical 
activity would be positively associated and sedentary behavior would be negatively associated 
with physical and cognitive function in older adults with MS and in healthy older adults. Such 
data would provide information on the magnitude of decline in physical and cognitive function in 
older adults with MS and identify whether physical activity or sedentary behavior might account 
for the differences in function. Therefore, this study would provide information to further 
facilitate clinical rehabilitation and behavioral interventions, such as physical activity, for the 
promotion of healthy aging in older adults with MS.  
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Chapter 3:  
Methods 
Participants 
 The sample included 40 community-dwelling older adults with MS and 40 age- and sex-
matched healthy controls aged 60 years and older. These participants were recruited from a 
mailing list of persons with MS in Illinois, a database of previous research volunteers, and a 
research advertisement posted on the website of the Greater Illinois chapter of the National 
Multiple Sclerosis Society (NMSS). The healthy controls were recruited through a campus-wide, 
email listserv. Participants were screened via telephone with the inclusion criteria for older adults 
with MS as: (a) 60 years of age and older; (b) diagnosis of MS; (c) relapse free in the last 30 
days; (d) ambulatory with or without assistance (i.e., walk independently or walk with a 
cane/rollator); (e) willing and able to visit the laboratory for one testing session. The inclusion 
criteria for the healthy controls was the same except for the diagnosis of MS and relapse free in 
the last 30 days. 
 
Measures of Physical Function 
 Timed 25-Foot Walk (T25FW). The T25FW was administered as a measure of walking 
speed as this measure has been identified as the best-characterized objective measure of 
ambulation in MS (Kiesseier & Pozzilli, 2012). Participants completed the T25FW twice, while 
walking as quickly as possible. The primary outcome was the average of the two walks (in 
seconds). 
 6-Minute Walk (6MW). The 6MW was administered as a measure of walking endurance 
as this measure is valid and reliable in persons with MS (Goldman et al., 2008). Participants 
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completed the 6MW as quickly as possible in a 75-foot hallway while performing 180° turns 
around cones placed at each end of the hallway. The primary outcome was total distance traveled 
(in feet). 
 Timed Up-and-Go (TUG). The TUG test was administered as an objective measure of 
functional mobility. This measure is routinely used in research with older adults (Podsiadlo & 
Richardson, 1991) and has been validated for use in persons with MS (Sebastiao et al., 2016). 
Participants completed the assessment by standing up from a chair (without the use of hands), 
walking 180° around a cone placed three meters in front of the chair, walking back to the chair, 
and then sitting down. If needed, participants were allowed to use assistive devices (i.e., cane or 
rollator) while performing the task. Participants were given two trials to complete the TUG test, 
and the average time across the two trials (in seconds) was computed as the final outcome.  
 6-Spot Step Test (6SST). The 6SST was administered as a measure of ambulatory 
function (Niewenhuis et al., 2006) as this measure has been validated in persons with MS 
(Sandroff et al., 2015). Participants completed the assessment by walking across a five-meter 
long and one-meter wide rectangular course, with five separate cones positioned on the ground, 
one and three meters from the starting line on the left side and two and four meters from the 
starting line on the right side, with the final cone positioned at the course’s midline, five meters 
from the start line. Participants kicked the cones off of the marked position with one foot, 
alternating between medial and lateral sides of the foot. Each participant completed the 6SST 
four times: twice using their dominant foot, and twice using their non-dominant foot to kick the 
cones. The primary outcome was the average of the four trials (in seconds). 
Short Physical Performance Battery (SPPB). The SPPB was administered as a measure 
of lower extremity function based on a three-part assessment, including standing balance, gait 
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speed, and chair rises (Guralnik et al., 1994; Guralnik et al., 1995). The SPPB has previously 
been validated in older adults (Guralnik et al., 1994) and older adults with MS (Motl et al., 
2015). Standing balance was assessed by asking participants to maintain upright posture for up to 
10 seconds per test while standing with feet in side-by-side, semi-tandem, and tandem positions. 
Those balance assessments occurred in a progressive order wherein participants needed to pass 
one test in order to attempt the subsequent, more challenging test. Gait speed was assessed based 
on the time taken by a participant to walk a four-meter course at a usual pace with the outcome 
of the fastest walk of two trials. Lower extremity strength was assessed by a chair stand test in 
which participants were instructed to sit in and fully rise from a chair five times as quickly as 
possible, without using arms for support. Participants were first asked to attempt and complete a 
single sit-and-rise before beginning the entire chair stand test. Performance scores for each SPPB 
individual assessment and a summary score aggregating the individual assessments was 
calculated as per standard SPPB protocol. Each of the three performance assessments was 
assigned a categorical score ranging from 0 (inability to complete a test) through 4 (highest level 
of performance) using standardized scoring, and the summary ranging between 0 and 12 was 
calculated by summing the standing balance, gait speed, and lower extremity strength categorical 
scores. Higher scores reflect better lower extremity function. 
 
Measures of Cognitive Function.  
The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). The 
BICAMS is a battery of three cognitive tests (Langdon et al., 2012) including measures of 
information processing speed (Symbol Digit Modalities Test (SDMT)) (Smith, 1982), verbal 
memory (California Verbal Learning Test-II (CVLT-II)) (Delis et al., 2000), and visual memory 
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(Brief Visuospatial Memory Test-Revised (BVMT-R)) (Benedict, 1997). The oral version of the 
SDMT involved pairing nine abstract geometric symbols with single digit numbers provided in a 
key. Participants were asked to voice correct numbers for unpaired symbols as quickly as 
possible for 90 seconds. Responses were recorded by the examiner, and the primary score was 
the total number of correct responses in 90 seconds. The CVLT-II involved the examiner reading 
a list of 16 randomly arranged words, with four words belonging to four categories (e.g., modes 
of transportation, furniture, animals, and vegetables) over five trials. After each trial, participants 
were instructed to recall as many words in any order. The overall score was expressed as the total 
number of correctly recalled words over the five trials. The BVMT-R involved three trials of the 
examiner presenting a 2 × 3 array of abstract of six geometric figures approximately 15 inches in 
front of the participant for 10 seconds. The examiner then removed the array and participants 
were asked to draw the array as precisely as possible, with the figures in the correct location. 
Each drawing was scored on a 0 to 2 scale, based on accurately drawing each figure and in the 
correct location. The primary outcome was the total score over the three trials, with a maximum 
score of 36. 
Paced Auditory Serial Addition Test (PASAT). The 3-second version of the PASAT 
(Fischer et al., 1999) was administered as an additional measure of information processing speed 
in the auditory domain. In the PASAT, a series of random single digit numbers were presented to 
the participants at the rate of one number every three seconds via an audio recording. Participants 
were instructed to say the sum of the last two numbers that were presented on the recording. 
Prior to testing, the examiner provided an example of how to perform the task correctly, ensuring 
that the participant understood not to give running totals, but the separate sums of the two most 
recent numbers presented. Up to three practice trials, consisting of 11 random numbers, were 
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completed by the participant prior to testing. During the actual test, a series of 61 random 
numbers were presented at the same rate. The primary outcome was the number of correct 
responses given, with a maximum score of 60. 
 
Sedentary Behavior & Physical Activity.  Sedentary behavior and physical activity were 
objectively measured with ActiGraph GT3X+ accelerometers (Health One Technology, Fort 
Walton Beach, FL). The accelerometers were initialized using the low-frequency extension 
feature as this increases the sensitivity for capturing low frequency accelerations (i.e., slow 
walking). The raw activity data were downloaded using software (ActiLife 8) and the data was 
processed into two separate Microsoft Excel files. One file represented daily accelerometer wear 
time and the other file represented time spent in sedentary behavior (≤99 counts/minute), LPA 
(100–1,722 counts/minute), and MVPA (i.e., ≥1,723 counts/minute) for older adults with MS 
and time spent in sedentary behavior (≤99 counts/minute), LPA (100–2,016 counts/minute), and 
MVPA (i.e., ≥2,017 counts/minute) for healthy controls (Sandroff et al., 2012).  These files 
further provided data on patterns of sedentary behavior and physical activity including number 
and average duration (minutes) of sedentary bouts (i.e., consecutive minutes with recorded 
counts of <100/minute sustained for more than 2 minutes); number and average duration 
(minutes) of long sedentary bouts (>30 minutes); and number and average duration (minutes) of 
activity bouts (i.e., >10 consecutive minutes with recorded counts of ≥100/minute) (Ezeugwu et 
al., 2015). Accelerometer wear time data were checked against participant recorded wear times 
from a log sheet and participants with ≥2 valid days (≥10 hours of wear time without periods of 
continuous zeros exceeding 60 minutes indicative of non-compliance) were included in the 
analysis (Motl et al., 2007). 
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Disability Status. All older adults with MS underwent a neurological exam by a Neurostatus-
certified examiner to generate Expanded Disability Status Scale (EDSS) scores (Kurtzke, 1983) 
for describing the disability status of the sample. 
 
Procedure 
 The procedure was approved by the Institutional Review Board at the University of 
Illinois Urbana-Champaign, and all participants provided written informed consent before 
participating in study procedures. Participants initially underwent the cognitive assessments, 
followed by the physical function assessments. The order of tests was standardized and 
participants were provided seated-rest between the administrations of the physical function 
assessments. Participants were then instructed to wear the accelerometer during waking hours 
and document wear time in a log book for a seven-day period after the testing session. 
Participants received $50 for completing the measures in the laboratory and $25 for wearing and 
returning the accelerometer. 
 
Data Analysis 
 Data were analyzed in SPSS Statistics Version 24 (IBM Corporation, Armonk, NY). To 
address the first hypothesis, group differences (i.e., older adults with MS vs. controls) in physical 
and cognitive function variables were examined using independent samples t-tests with the 
differences between groups expressed using Cohen’s d (difference in mean scores divided by the 
pooled SD) with values of 0.2, 0.5, and 0.8 representing small, moderate, and large differences, 
respectively (Cohen, 1988). To address the second hypothesis, group differences (i.e., older 
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adults with MS vs. controls) in physical activity and sedentary behavior variables were examined 
using analysis of covariance (ANCOVA) with condition (Group: MS or Control) as the between 
subjects factor and accelerometer wear time (minutes) as the covariate. Effect sizes for the F-
statistic were also expressed using Cohen’s d with values of 0.2, 0.5, and 0.8 representing small, 
moderate, and large differences, respectively (Cohen, 1988). To address the third hypothesis, 
partial Pearson correlations (pr), controlling for accelerometer wear time, were conducted among 
physical and cognitive function variables, physical activity, and sedentary behavior. Values for 
correlation coefficients of 0.1, 0.3, and 0.5 were interpreted as weak, moderate, and strong, 
respectively (Cohen, 1988). To further examine if physical activity and/or sedentary behavior 
account for any differences between older adults with MS vs. healthy controls on function 
outcomes, a hierarchal linear regression was performed. This was undertaken by regressing 
physical and cognitive function variables on group (i.e., older adults with MS vs. healthy 
controls) in Step 1 and then adding physical activity and sedentary behavior variables in Step 2. 
The β-coefficients for physical and cognitive function variables were compared between Step 1 
and Step 2 to examine if physical activity and/or sedentary behavior accounted for the 
differences between group (i.e., older adults with MS and healthy controls). 
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Chapter 4: 
Results 
Participant Characteristics 
 Demographic and clinical characteristics of the sample are presented in Table 1. Briefly, 
the mean (SD) age for older adults with MS and controls were similar (65.3 (4.3) and 66.5 (6.7), 
respectively). Both older adults with MS and controls had similar body mass index (28.5 (6.9) 
and 27.1 (5.0), respectively) and were primarily composed of women (n = 25/40; 62.5%). Older 
adults with MS had predominantly relapsing-remitting MS (RRMS), a mean (SD) disease 
duration of 21.5 (8.6) years, and moderate disability based on the median EDSS score (4.0 (IQR 
= 2.0)). 
 
Physical and Cognitive Function, Physical Activity, and Sedentary Behavior 
Descriptive data and statistical analyses of physical and cognitive function, physical 
activity, and sedentary behavior for older adults with MS and age- and sex-matched healthy 
controls are presented in Table 2. In regards to physical function, older adults with MS 
performed significantly worse on all measures compared to controls, with moderate differences 
for the balance (d = 0.6) and gait speed (d = 0.7) components of the SPPB, and large differences 
for the T25FW (d = 1.0), 6MW (d = 1.6), TUG (d = 0.9), 6SST (d = 1.0), total SPPB score (d = 
1.3), and the chair rises component of the SPPB (d = 1.4).  Regarding cognitive function, older 
adults with MS performed significantly worse on the SDMT (i.e., measure of information 
processing speed) compared to controls (48.3 (11.2) vs. 55.0 (7.8), respectively) and this effect 
was moderate in magnitude (d = 0.7). There were no statistically significant differences for the 
other measures of cognitive function.  
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Both older adults with MS and controls had similar number of days of valid 
accelerometer data (i.e., 10 hours of wear time without periods of continuous zeros exceeding 60 
minutes indicative of non-compliance). However, wear time (minutes/day) was significantly 
different between groups, such that older adults with MS wore the accelerometer approximately 
50 minutes less per day compared to controls (797.8 (97.8) vs. 851.8 (79.3)), respectively). 
When controlling for accelerometer wear time (minutes/day), older adults with MS engaged in 
approximately 23 minutes less MVPA per day compared to controls (12.6 (14.1) vs. 35.7 (23.0)), 
and this effect was large in magnitude (d = 1.2). Older adults with MS further spent 
approximately 5 minutes more in sedentary behavior per day compared to controls (539.7 (84.7) 
vs. 534.4 (81.8)) and this effect was weak in magnitude (d = 0.1). There were no statistically 
significant differences in LPA (minutes/day) or any patterns of physical activity or sedentary 
behavior between older adults with MS and controls. 
 
Physical Activity and Physical and Cognitive Function 
The associations among physical and cognitive function and physical activity in older 
adults with MS and age- and sex-matched healthy controls are presented in Table 3. The partial 
Pearson correlations (pr), controlling for accelerometer wear time (minutes), indicated 
statistically significant and moderate-to-large associations between LPA (minutes/day) and a 
majority of physical function variables (e.g., T25FW, 6MW, TUG, 6SST, gait speed and chair 
rises components of SPPB) in older adults with MS (pr = 0.39−0.54). In controls, LPA 
(minutes/day) was only significantly associated with total SPPB score (pr = 0.42) and the 
balance (pr = 0.38) and chair rises (pr = 0.38) components of the SPPB. The partial Pearson 
correlations further indicated significant and similar associations between MVPA (minutes/day) 
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and a majority of physical function variables (e.g., T25FW, 6MW, TUG, 6SST, and total SPPB 
score) in both older adults with MS (pr = 0.37−0.59) and controls (pr = 0.34−0.55). MVPA was 
also significantly associated with the gait speed component of the SPPB in older adults with MS 
(pr = 0.42) and the chair rises component of the SPPB in controls (pr = 0.46). There were further 
significant moderate-to-large associations between number of activity bouts/day and all physical 
function variables, with the exception of the balance component of the SPPB, in older adults 
with MS (pr = 0.39−0.56), but no significant associations in controls. The TUG, 6SST, total 
SPPB score and gait speed and chair rises components of the SPPB were significantly associated 
with duration of activity bouts (minutes/day) in older adults with MS (pr = 0.33−0.41); there 
were no significant associations in controls. In regards to cognitive function, the only significant 
associations were between SDMT and number of activity bouts/day in older adults with MS (pr 
= 0.39) and MVPA (minutes/day) in controls (pr = 0.37). 
 
Sedentary Behavior and Physical and Cognitive Function 
The associations among physical and cognitive function and sedentary behavior in older 
adults with MS and age- and sex-matched healthy controls are presented in Table 4. The partial 
Pearson correlations, controlling for accelerometer wear time (minutes), indicated statistically 
significant and moderate associations between sedentary behavior (minutes/day) and two 
physical function variables in older adults with MS, including the 6MW (pr = -0.33) and the 
TUG (pr = 0.33); there were no significant associations in controls. The partial Pearson 
correlations also indicated significant and moderate associations between the duration of 
sedentary bouts (minutes) and all physical function variables, with the exception of the balance 
component of the SPPB, in older adults with MS (pr = 0.39−0.49), but no significant 
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associations in controls.  There were significant and moderate associations between the number 
of long (≥30 minutes) sedentary bouts/day and physical function variables in older adults with 
MS (e.g., T25FW, 6MW, TUG, 6SST, and the gait speed and chair rises components of the 
SPPB; pr = 0.33−0.40) and in controls (e.g., total SPPB score (pr = -0.35) and the balance 
component of the SPPB (pr = -0.38).  The partial Pearson correlations further indicated 
significant and moderate-to-large associations between the duration of long sedentary bouts 
(minutes) and all physical function variables, with the exception of the balance component of the 
SPPB, in older adults with MS (pr = 0.44−0.62), but no significant associations in controls. 
There was one significant association between number of sedentary bouts/day and the balance 
component of the SPPB in older adults with MS (pr = 0.36) but no significant associations in 
controls. There were no significant associations between any of the cognitive function variables 
and sedentary behavior measures.  
 
Linear Regression 
 All physical and cognitive function variables that were significantly different between 
older adults with MS and controls (i.e., T25FW, 6MW, TUG, 6SST, SPPB, and SDMT) were 
regressed on sedentary behavior and MVPA (minutes/day). The regression analyses indicated 
that MVPA (minutes/day) partially accounted for the effect of group (older adults with MS vs. 
controls) on the significantly different physical and cognitive function variables (Table 5). 
However, sedentary behavior (minutes/day) did not make any contribution beyond MVPA in 
explaining group differences in physical and cognitive function. For example, when the 6MW 
was regressed on Group in Step 1, the β-coefficient was statistically significant (β = -0.64, p < 
0.05); when MVPA (minutes/day) was added in Step 2, the β-coefficient become attenuated, but 
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still significant (β = -0.40, p < 0.05). However, when sedentary behavior (minutes/day) was also 
added in Step 2, the β-coefficient remained the same. When the SDMT was regressed on Group 
in Step 1, the β-coefficient was statistically significant (β = -0.32, p < 0.05); when MVPA 
(minutes/day) was added in Step 2, the β-coefficient become attenuated and no longer 
statistically significant (β = -0.17, p = 0.17). Further, when sedentary behavior (minutes/day) was 
also added in Step 2, the β-coefficient remained the same.  
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Chapter 5: 
Discussion 
The current study examined physical and cognitive function in older adults with MS (i.e., 
60 years of age and older) compared to age- and sex-matched healthy older adults in the general 
population and the extent to which objectively measured physical activity and sedentary behavior 
were associated with these functions. The primary results of the present study were: (a) older 
adults with MS demonstrated greater impairments in all measures of physical function compared 
to healthy controls, including the T25FW, 6MW, TUG, 6SST, total SPPB score and components 
(i.e., balance, gait speed, and chair rises); (b) older adults with MS only demonstrated greater 
impairment in one measure of cognitive function compared to healthy controls (i.e., the SDMT 
as a measure of information processing speed); (c) older adults with MS engaged in less MVPA 
(minutes) per day and more sedentary behavior (minutes) per day compared to healthy controls 
with no differences in patterns of physical activity (i.e., activity bouts), LPA (minutes/day), or 
patterns of sedentary behavior (i.e., sedentary bouts); (d) physical activity, specifically 
minutes/day of LPA and MVPA, and the number and duration of activity bouts/day were 
significantly associated with a majority of physical function variables but not cognitive function 
variables in both older adults with MS and healthy controls but to a greater extent in older adults 
with MS; (e) sedentary behavior, specifically the duration of sedentary bouts (minutes), number 
of long (≥30 minutes) sedentary bouts/day and the duration of long sedentary bouts (minutes) 
were significantly associated with a majority of physical function variables but not cognitive 
function variables primarily in older adults with MS; and (f) MVPA (minutes/day), but not 
sedentary behavior (minutes/day) partially explained the differences in physical and cognitive 
function between older adults with MS and healthy controls. 
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The result that older adults with MS demonstrate greater impairments in all objective 
measures of physical function compared to healthy controls is largely in agreement with previous 
research (Minden et al., 2004). Importantly, all measures demonstrated either moderate (e.g. 
balance and gait speed components of the SPPB) or large differences (e.g., T25FW, 6MW, TUG, 
6SST, total SPPB score, and chair rises component of the SPPB) between older adults and 
healthy controls based on effect size (d). Regarding the T25FW, older adults with MS completed 
the assessment in 7.9 (5.4) seconds, and previous research demonstrated that a T25FW time of 
6.0 to 7.99 seconds was associated with occupational disability and needing “some help” with 
instrumental activities of daily living in a sample of 159 middle-aged adults with MS (Goldman 
et al., 2013). Further, a previous systematic review of factors associated with falls in persons 
with multiple sclerosis demonstrated a mean T25FW time ranged from 6.9 to 8.4 seconds and 
from 5.8 to 6.9 seconds in fallers and non-fallers, respectively, according to four different studies 
(standard mean difference (SMD) = 0.45; 95% CI = 0.20−0.70, p < 0.0005) (Gianni et al., 2014). 
This same review further demonstrated mean TUG scores ranged from 2.7 to 12.5 seconds and 
from 2.5 to 11.4 seconds in fallers and non-fallers, respectively, according to three different 
studies (SMD = 0.31; 95% CI = 0.01−0.60, p = 0.04) (Gianni et al., 2014). The current sample of 
older adults had a mean (SD) TUG time of 12.6 (10.0) seconds, compared to 6.0 (1.2) seconds in 
healthy controls (d = 4.1). Therefore, the current sample of older adults with MS may be at an 
increased risk of falling as falls are very common in persons with MS. For the SPPB, the mean 
(SD) total score of 9.0 (2.5) and component scores (i.e., balance: 3.5 (0.9), gait speed: 3.5 (1.0), 
and chair rises: 2.0 (1.3) in older adults with MS were similar to scores previously reported in a 
sample of 48 older adults with MS (59.5 (5.8) years of age; Motl et al., 2015). Further, the mean 
total SPPB score of 9.0 in the current sample of older adults with MS was below the cut-off 
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value of 10.0, indicating elevated risk for developing future disability (Guralnik et al., 2000). Of 
note, the lower extremity strength (i.e., chair rises) component of the SPPB demonstrated the 
largest decrement in physical function in older adults with MS compared to healthy controls.  
In contrast to the measures of physical function, older adults performed worse in only one 
measure of cognitive function (i.e., the SDMT as a measure of information processing speed) 
compared to healthy controls. The mean (SD) score of 48.3 (11.2) on the SDMT in older adults 
with MS was ~7 points less than the mean (SD) score of 55.0 (7.8) in healthy controls.  Further, 
the mean SDMT scores for older adults with MS and healthy controls was 0.18 SD-units below 
and 0.60 SD-units above the regression-based normative value (controlled for age, sex, and 
education), respectively. Therefore, both older adults with MS and healthy controls, on average, 
were not cognitively impaired (> 1.5 SD-units below the regression-based normative value) 
(Parmenter et al., 2009). This result is similar to a previous study that demonstrated older adults 
with MS (59–74 years of age) performed worse on a different measure of information processing 
speed (i.e., Stroop Color and Word Naming Tests) compared to healthy age- and sex-matched 
controls (Bodling et al., 2009). However, as older adults with MS performed worse than healthy 
controls on only one measure of cognitive function compared to all measures of physical 
function, older adults with MS may be at a higher risk of motor dysfunction compared to 
cognitive dysfunction. Our results supplement a recent study that demonstrated the aging process 
may affect physical and cognitive function differently in persons with MS (Roy et al., 2016). 
Previous research has identified hypotheses for this discrepancy in worsened physical and 
cognitive function in older adults with MS, such as pathological changes specifically impacting 
physical function as well as the influence of cognitive reserve (Sanai et al., 2010; Roy et al., 
2016); however, the underlying cause is still ambiguous.  
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Importantly, the results of the current study further suggest that physical activity, namely 
MVPA (minutes/day), might partially influence the magnitude of differences in both physical 
and cognitive function between older adults with MS and healthy controls. Previous research 
demonstrated that older adults with MS engage in less MVPA and more sedentary behavior per 
day compared to young and middle-aged adults with MS (Klaren et al., 2016); however, the 
current study is novel in that older adults with MS also engaged in less MVPA (minutes) per day 
and more sedentary behavior (minutes) per day compared to age- and sex-matched healthy 
controls. The difference in MVPA between older adults with MS and healthy controls was quite 
large, whereas the difference in sedentary behavior was rather small. The older adults with MS 
engaged in 12.6 (14.1) minutes of MVPA/day whereas healthy controls engaged in 35.7 (23.0) 
minutes of MVPA/day (d = 1.2). The current results demonstrate that older adults with MS, on 
average, are not meeting the public health guidelines for MVPA (i.e., ³30 minutes/day of 
MVPA) and therefore are not reaping the public health benefits of physical activity.  
Older adults with MS further engaged in 539.7 (84.7) minutes of sedentary behavior/day 
whereas healthy controls engaged in 534.4 (81.8) minutes (d = 0.1). These results agree with a 
recent meta-analysis that demonstrated persons with MS are less physically active than non-
diseased populations (effect size (ES) = -0.57, 95% CI = -0.76−-0.37; Kinnett-Hopkins et al., 
2017). There were no statistically significant differences in patterns of physical activity (i.e., 
activity bouts), LPA (minutes/day), or patterns of sedentary behavior (i.e., sedentary bouts). 
Further, when the physical and cognitive function variables were regressed on MVPA and 
sedentary behavior (minutes/day), only MVPA partially contributed to the differences between 
older adults with MS and healthy controls on physical and cognitive function. Therefore, these 
results highlight the need for behavioral interventions in older adults with MS to largely focus on 
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increasing MVPA as well as decreasing sedentary behavior, with the overall goal of managing 
the progression and consequences of the disease, including impairments in physical and 
cognitive function. 
Physical activity, specifically minutes/day of LPA and MVPA, and the number and 
duration of activity bouts/day were significantly associated with most physical function variables 
in both older adults with MS and healthy controls, but to a greater extent in older adults with MS. 
This result is somewhat surprising as much previous research has demonstrated physical activity 
to be associated with physical function in healthy older adults (Taylor et al., 2004) and in older 
adults with chronic diseases (de Vries et al., 2012). While there were few associations among 
minutes/day of LPA and MVPA and physical function variables in the healthy controls, there 
were no associations among patterns of physical activity (i.e., number or duration of activity 
bouts/day) and physical function. By comparison, both levels (i.e., minutes/day of LPA and 
MVPA) and patterns (i.e., number or duration of activity bouts/day) of physical activity were 
associated with almost all physical function variables in older adults with MS. Perhaps there is 
more opportunity for associations in older adults with MS as older adults with MS have greater 
impairments in physical function compared to healthy controls; therefore, there is less of a 
ceiling effect for associations with physical activity in older adults with MS. Regarding the 
cognitive function variables, there were only two significant associations between SDMT and 
minutes/day of MVPA in healthy controls and SDMT and number of activity bouts/day in older 
adults with MS. This result is very unexpected and contradicts previous research that 
demonstrated associations between physical activity and cognitive function in adults with MS 
(Morrison & Mayer, 2016) and in healthy older adults in the general population (Bherer et al., 
2013). Overall, these results are novel and suggest that behavioral interventions in older adults 
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with MS should not only focus on increasing levels of both LPA and MVPA, but also on activity 
bouts throughout the day, as means for potentially improving physical function. 
 Sedentary behavior, specifically the duration of sedentary bouts (minutes), number of 
long (≥30 minutes) sedentary bouts/day, and the duration of long sedentary bouts (minutes) were 
significantly associated with many physical function variables but not cognitive function 
variables primarily in older adults with MS. The lack of associations among sedentary behavior 
and physical and cognitive function in healthy controls is again surprising as previous research 
has demonstrated sedentary time to be strongly associated with diminished physical (Seguin et 
al., 2012) and cognitive (Vance et al., 2005) function in healthy older adults. The associations 
between sedentary behavior and physical function in older adults with MS, however, is much in 
agreement with previous research. For example, one study demonstrated that greater sedentary 
time (minutes/day) was significantly correlated with lower 6MW distance and slower T25FW in 
middle-aged adults with MS (Hubbard & Motl, 2015). The current study is novel in that patterns 
of sedentary behavior (i.e., sedentary bouts) were also moderately associated with physical 
function and support the notion that transitions from sedentary to non-sedentary behavior are 
important for physical function in addition to cardiometabolic health (Healy et al., 2011). The 
lack of associations among sedentary behavior and cognitive function in older adults with MS is 
similar to a previous study that also demonstrated no associations between sedentary behavior 
(minutes/day) and cognitive function (i.e., SDMT performance) in middle-aged adults with MS 
(Hubbard & Motl, 2015). However, there is very limited research on sedentary behavior in older 
adults in the general population as well as older adults with MS that warrants continued research 
on prospective associations with physical and cognitive function. 
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 The current study involved a relatively large sample size, direct comparisons of older 
adults with MS and age- and sex-matched healthy controls, and objective and comprehensive 
measurements of sedentary behavior, physical activity, and physical and cognitive function. 
However, there are several limitations. Firstly, this study utilized a cross-sectional research 
design and therefore the results of this study only suggest correlations among sedentary behavior, 
physical activity, and function but no determination of causation. The results cannot determine 
whether sedentary behavior and physical activity influence physical and cognitive function or 
vice versa. The current sample of older adults with MS and healthy controls were relatively 
young (65.3 (4.3) and 66.5 (6.7) years of age, respectively) and perhaps the results may not be 
fully generalized to older adults greater than 65-70 years of age. Further, the majority of the 
sample of older adults with MS had mild-to-moderate disability (i.e., EDSS score 3.5-5.5; 60%) 
and therefore the current results may also not be generalized to older adults with higher levels of 
disability. Lastly, the current study did not include other measures that may have affected the 
associations of sedentary behavior, physical activity, and physical and cognitive function, such 
as fatigue, which is highly prevalent in persons with MS (Bakshi, 2003). 
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Chapter 6:  
Conclusions 
 The current study demonstrated older adults with MS (i.e., 60 years of age and older) had 
greater impairments in many areas of physical function (i.e., walking speed and endurance and 
lower extremity strength) but only one area of cognitive function (i.e., information processing 
speed) compared to age- and sex-matched healthy controls. Older adults with MS further 
engaged in lower levels of MVPA (minutes/day) and higher levels of sedentary behavior 
(minutes/day) compared to healthy controls. Both levels and patterns of physical activity and 
sedentary behavior were associated with physical function to a greater extent in older adults with 
MS compared to healthy controls. Importantly, the low levels of MVPA in older adults with MS 
partially contributed to the differences in physical and cognitive function. Overall, such results 
identify a large decline in physical function, but not cognitive function in older adults with MS 
compared to healthy controls, and that both levels and patterns of physical activity and sedentary 
behavior should be an emphasis of clinical rehabilitation and behavioral interventions for the 
promotion of healthy aging in older adults with MS. 
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Chapter 7: 
Figure and Tables 
 
Figure 1.  Mechanisms of aging and MS on physical and cognitive function and the 
potential effects of physical activity and sedentary behavior. 
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Table 1. Demographic and clinical characteristics of the older adults with MS and age- and 
sex-matched healthy controls 
Variable MS (n=40) Controls (n=40) 
Age, years 65.3 (4.3) 66.5 (6.7) 
Sex, % female (n=) 62.5 (n=25) 62.5 (n=25) 
BMI (kg/m2) 28.5 (6.9) 27.1 (5.0) 
MS Type, % RRMS 67.5  
EDSS score (mdn, IQR) 4.0 (2.0)  
   0−3.0 (n=, %) 8 (20.0)  
   3.5−5.5 (n=, %) 24 (60.0)  
   6−8.0 (n=, %) 8 (20.0)  
MS Duration, years 21.5 (8.6)  
AD Use, % 25.0 0.0 
Note. Data presented as mean (SD), unless otherwise noted. MS=multiple sclerosis; BMI=body 
mass index; RRMS=relapsing-remitting MS; EDSS=Expanded Disability Status Scale; 
AD=assistive device 
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Table 2. Descriptive characteristics and statistical analyses of physical and cognitive 
function and physical activity and sedentary behavior in older adults with MS and age- and 
sex-matched healthy controls 
Variable MS (n=40) Controls (n=40) t-value d-value 
Physical Function     
T25FW, seconds 7.9 (5.4) 4.3 (0.6) 4.3* 1.0 
6MW, feet 1318.8 (447.0) 1938.0 (291.7) 7.3* 1.6 
TUG, seconds 12.6 (10.0) 6.0 (1.2) 4.1* 0.9 
6SST, seconds 14.6 (11.2) 6.8 (1.4) 4.3* 1.0 
SPPB 9.0 (2.5) 11.4 (1.0) 5.8* 1.3 
  Balance 3.5 (0.9) 3.9 (0.4) 2.6* 0.6 
  Gait Speed 3.5 (1.0) 4.0 (0.2) 3.2* 0.7 
  Chair Rises 2.0 (1.3) 3.5 (0.7) 6.4* 1.4 
Cognitive Function     
SDMT 48.3 (11.2) 55.0 (7.8) 3.1* 0.7 
CVLT-II 49.9 (11.5) 52.5 (8.8) 1.2 0.3 
BVMT-R 18.5 (7.0) 19.6 (5.9) 0.8 0.2 
PASAT 41.2 (12.4) 43.7 (11.6) 0.9 0.2 
Accelerometry     
Number of valid days 5.9 (1.7) 6.5 (1.1) 2.0 0.4 
Wear time, minutes 797.8 (97.8) 851.8 (79.3) 2.7* 0.6 
 
 MS (n=40) Controls (n=40) F-value d-value 
Physical Activity     
LPA, minutes/day 245.5 (76.5) 281.6 (70.3) 0.9 0.5 
MVPA, minutes/day 12.6 (14.1) 35.7 (23.0) 20.5* 1.2 
Number of activity bouts/day 12.4 (4.9) 13.4 (3.7) 0.02 0.2 
Duration of activity bouts, 
minutes 
45.9 (29.5) 43.4 (28.2) 0.03 0.1 
Sedentary Behavior     
Sedentary behavior, 
minutes/day 
539.7 (84.7) 534.4 (81.8) 4.3* 0.1 
Number of sedentary bouts 15.2 (3.2) 15.7 (3.1) 0.5 0.2 
Duration of sedentary bouts, 
minutes 
24.5 (7.3) 22.9 (3.9) 0.7 0.3 
Number of long (≥30 minutes) 
sedentary bouts 
5.9 (1.4) 5.5 (1.9) 2.8 0.2 
Duration of long sedentary 
bouts, minutes 
51.4 (8.2) 47.8 (6.0) 2.9 0.5 
Note. Data presented as mean (SD). *Denotes statistical significance, p<0.05. MS=multiple 
sclerosis; T25FW=Timed 25-Foot Walk; 6MW=Six-Minute Walk; TUG=Timed Up-and-Go; 
6SST=Six-Spot Step Test; SPPB=Short Physical Performance Battery; SDMT=Symbol Digit 
Modalities Test; CVLT-II=California Verbal Learning Test-II; BVMT-R=Brief Visuospatial 
Memory Test-Revised; PASAT=Paced Auditory Serial Addition Test; LPA=light physical 
activity; MVPA=moderate-to-vigorous physical activity 
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Table 3. Correlations among physical activity and physical and cognitive function in older 
adults with MS (n=40) and age- and sex-matched healthy controls (n=40) 
Variable Physical Activity 
 LPA, 
minutes/day 
MVPA, 
minutes/day 
Number of activity 
bouts/day 
Duration of 
activity bouts, 
minutes/day 
Physical 
Function 
    
T25FW, seconds -0.53*, -0.14 -0.39*, -0.34* -0.54*, 0.17 -0.27, -0.02 
6MW, feet 0.42*, 0.13 0.59*, 0.55* 0.39*, -0.07 0.18, -0.08 
TUG, seconds -0.52*, -0.30 -0.37*, -0.48* -0.63*, 0.04 -0.38*, 0.09 
6SST, seconds -0.54*, -0.14 -0.39*, -0.43* -0.60*, -0.10 -0.34*, -0.20 
SPPB 0.39*, 0.42* 0.42*, 0.44* 0.56*, -0.12 0.34*, -0.12 
  Balance -0.09, 0.38* 0.29, 0.26 0.22, -0.17 -0.04, -0.03 
  Gait Speed 0.47*, 0.04 0.42*, 0.05 0.55*, -0.24 0.33*, -0.03 
  Chair Rises 0.44*, 0.38* 0.27, 0.46* 0.50*, -0.03 0.41*, -0.14 
Cognitive 
Function 
    
SDMT 0.19, 0.28 0.21, 0.37* 0.40*, 0.01 0.21, -0.21 
CVLT-II -0.08, 0.13 0.02, 0.03 0.07, -0.18 -0.01, -0.01 
BVMT-R 0.06, 0.04 0.17, 0.10 0.09, -0.18 0.20, -0.06 
PASAT -0.02, 0.07 0.27, 0.15 0.29, -0.21 0.12, -0.06 
Note. Partial Pearson product-moment correlations (pr), controlling for accelerometer wear time 
(minutes). *Denotes statistical significance, p<0.05. Data presented as MS, controls. 
MS=multiple sclerosis; T25FW=Timed 25-Foot Walk; 6MW=Six-Minute Walk; TUG=Timed 
Up-and-Go; 6SST=Six-Spot Step Test; SPPB=Short Physical Performance Battery; 
SDMT=Symbol Digit Modalities Test; CVLT-II=California Verbal Learning Test-II; BVMT-
R=Brief Visuospatial Memory Test-Revised; PASAT=Paced Auditory Serial Addition Test; 
LPA=light physical activity; MVPA=moderate-to-vigorous physical activity 
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Table 4. Correlations among sedentary behavior and physical and cognitive function in 
older adults with MS (n=40) and age- and sex-matched healthy controls (n=40) 
Variable Sedentary Behavior 
 Sedentary 
behavior, 
minutes/day 
Number of 
sedentary 
bouts 
Duration of 
sedentary 
bouts, 
minutes 
Number of 
long (≥30 
minutes) 
sedentary 
bouts 
Duration of 
long 
sedentary 
bouts, 
minutes 
Physical 
Function 
     
T25FW, seconds 0.29, 0.10 -0.06, 0.11 0.49*, -0.07 0.37*, 0.06 0.56*, 0.01 
6MW, feet -0.33*, -0.03 -0.01, -0.09 -0.45*, 0.20 -0.37*, 0.03 -0.56*, 0.10 
TUG, seconds 0.33*, 0.14 -0.01, 0.09 0.48*, 0.06 0.42*, 0.10 0.51*, 0.20 
6SST, seconds 0.31, 0.03 -0.02, 0.06 0.49*, -0.11 0.40*, -0.07 0.56*, 0.09 
SPPB -0.18, -0.24 0.14, -0.27 -0.45*, -0.07 -0.31, -0.35* -0.56*, 0.02 
  Balance 0.18, -0.26 0.36*, -0.23 -0.23, -0.12 0.07, -0.38* -0.17, -0.02 
  Gait Speed -0.25, -0.14 0.04, -0.20 -0.39*, 0.02 -0.33*, -0.15 -0.44*, 0.01 
  Chair Rises -0.28, -0.17 -0.01, -0.21 -0.39*, -0.04 -0.37*, -0.26 -0.62*, 0.03 
Cognitive 
Function 
     
SDMT 0.01, -0.08 0.09, -0.12 -0.22, -0.11 -0.17, -0.08 -0.05, -0.21 
CVLT-II 0.30, -0.08 0.24, -0.17 0.01, -0.10 0.22, -0.27 0.04, -0.02 
BVMT-R -0.03, 0.05 0.08, -0.04 -0.08, 0.10 -0.02, 0.02 -0.02, 0.11 
PASAT 0.14, -0.08 0.20, -0.08 -0.18, 0.01 0.03, -0.09 0.08, -0.01 
Note. Partial Pearson product-moment correlations (pr), controlling for accelerometer wear time 
(minutes). *Denotes statistical significance, p<0.05. Data presented as MS, controls. 
MS=multiple sclerosis; T25FW=Timed 25-Foot Walk; 6MW=Six-Minute Walk; TUG=Timed 
Up-and-Go; 6SST=Six-Spot Step Test; SPPB=Short Physical Performance Battery; 
SDMT=Symbol Digit Modalities Test; CVLT-II=California Verbal Learning Test-II; BVMT-
R=Brief Visuospatial Memory Test-Revised; PASAT=Paced Auditory Serial Addition Test 
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Table 5. Summary of linear regression analyses of physical and cognitive function and 
MVPA in older adults with MS (n=40) and age- and sex-matched healthy controls (n=40) 
 T25FW, seconds 6MW, feet TUG, seconds 
Variable B (SE B) β B (SE B) β B (SE B) β 
Step 1 (Group) 3.66 (0.87) 0.43* -616.84 (85.80) -0.64* 6.63 (1.61) 0.43* 
Step 2a (Group) 2.58 (1.0) 0.31* -383.87 (86.35) -0.40* 4.57 (1.84) 0.29* 
Step 2b (MVPA 
(minutes/day)) 
-0.05 (0.02) -0.25* 10.19 (1.95) 0.47* -0.09 (0.04) -0.25* 
 
 6SST, seconds SPPB SPPB Balance 
 B (SE B) β B (SE B) β B (SE B) β 
Step 1 (Group) 7.77 (1.80) 0.44* -2.45 -0.55* -0.41 -0.29* 
Step 2a (Group) 5.37 (2.06) 0.31* -1.67 -0.37*   
Step 2b (MVPA 
(minutes/day)) 
-0.10 (0.05) -0.26* 0.03 0.33*   
 
 SPPB Gait Speed SPPB Chair Rises SDMT 
 B (SE B) β B (SE B) β B (SE B) β 
Step 1 (Group) -0.54 -0.35* -1.50 -0.58* -6.54 -0.32* 
Step 2a (Group)   -1.10 -0.42* -3.41 -0.17 
Step 2b (MVPA 
(minutes/day)) 
  0.02 0.30* 0.14 0.30* 
Note. *Denotes statistical significance, p<0.05. MS=multiple sclerosis; T25FW=Timed 25-Foot 
Walk; 6MW=Six-Minute Walk; TUG=Timed Up-and-Go; 6SST=Six-Spot Step Test; 
SPPB=Short Physical Performance Battery; SDMT=Symbol Digit Modalities Test 
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